摘要
目的探讨伊立替康单药二线治疗进展期结直肠癌的临床效果。方法选取2011年1月～2013年1月本院收治的进展期结直肠癌患者50例,给予伊立替康90 mg/m2,静脉滴注,第1、8天,每21天重复。2个疗程后评价治疗效果。化疗前常规止吐。结果本组50例患者,无完全缓解(CR)患者,其中,部分缓解(PR)12例(24%),稳定(SD)26例(52%),进展(PD)12例(24%),总有效(CR+PR)率为24%,疾病控制(CR+PR+SD)率为76%。均未出现药物所致死亡及严重不良事件,其中血液学毒性为骨髓抑制Ⅰ+Ⅱ度中性粒细胞减少症29例(58%),Ⅲ+Ⅳ度中性粒细胞减少症7例(14%);非血液学毒性为Ⅰ+Ⅱ度迟发性腹泻18例(36%),Ⅲ+Ⅳ度迟发性腹泻3例(6%),Ⅰ+Ⅱ度恶心呕吐29例(58%),Ⅲ+Ⅳ度恶心呕吐4例(8%)。结论伊立替康单药二线治疗进展期结直肠癌,效果显著,不良反应轻微。
Objective To investigate the clinical effect of irinotecan single-agent second-line treatment on advanced coloreetal cancer. Methods 50 patients were admitted to hospital with advanced colorectal cancer from January 2011 to January 2013 and given irinotecan 90 mg/m2,intravenous infusion,day 1,8,repeated every 21 days.The treatment ef- fect were evaluated after two courses of treatment.Results Of the 50 patients,there were no complete remission （CR） patients,partial remission （PR） were 12 cases （24%）,stable （SD） were 26 cases （52%）,progression （PD） were 12 cases （24%）,the total effective rate （CR＋PR） was 24%,disease control rate （CR＋PR＋SD） was 76%.There were no due to the emergence of drug death and serious adverse events.Hematologic toxicity was myelosuppression I ＋ U degree of neu- tropenia disease,were 29 cases （58%）,11l ＋IV degree of neutropenia disease in 7 patients （14%）; non-hematologic toxi- city I ＋ II degree delayed diarrhea in 18 cases （36%）,Ill＋IV degree of delayed diarrhea in 3 cases （6%）, I ＋ II degree of nausea and vomiting in 29 cases （58%）,lU＋IV degree of nausea and vomiting in 4 cases （8%）.Conclusion Irinote- can single-agent second-line treatment of advanced colorectal cancer has the significant effect,the adverse reactions are mild.
出处
《中国当代医药》
2013年第27期64-65,共2页
China Modern Medicine
关键词
伊立替康
二线治疗
进展期结直肠癌
Irinotecan
Second-line treatment
Advanced colorectal cancer
